The ubiquitin-proteasome system--micro target for macro intervention?
The ubiquitin-proteasome system is the two sequential labeling and degradation system that accounts for the degradation of 80-90% of all intracellular proteins. Based on the diversity of its substrates, it is integrated in many different biological processes, especially inflammation and cell proliferation. Given the significance of these two processes for primary atherosclerosis and restenosis, the ubiquitin-proteasome system may be an amendable target in cardiovascular therapy. This review provides background information on the ubiquitin-proteasome system, currently available data on its involvement in cardiovascular diseases, and a future perspective on the targeted use proteasome inhibitors, including drug-eluting stents.
Herrmann
Joerg
J
Division of Cardiovascular Diseases Mayo Clinic, Rochester, MN 55905, USA. herrmann.joerg@mayo.edu
Ciechanover
Aaron
A
Lerman
Lilach O
LO
Lerman
Amir
A
D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D015415:Biomarkers; D001707:Biopsy, Needle; D049109:Cell Proliferation / Q000187:drug effects; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000201:enzymology* / Q000473:pathology; D003331:Coronary Vessels / Q000201:enzymology* / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D011379:Prognosis; D011480:Protease Inhibitors / Q000627:therapeutic use; D046988:Proteasome Endopeptidase Complex / Q000627:therapeutic use; D061988:Proteasome Inhibitors; D012680:Sensitivity and Specificity; D043743:Ubiquitin-Protein Ligase Complexes / Q000378:metabolism*
D015415:Biomarkers; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D043743:Ubiquitin-Protein Ligase Complexes; D046988:Proteasome Endopeptidase Complex